Clustered analysis of Fabry disease progression in a large US electronic health records database (Optum Market Clarity): A retrospective observational cohort study
Event: WORLD Symposium 2022, San Diego, CA, USA Authors: A. Chiorean, S. Kabadi, P. Hayat, M. Montmerle, E. Ponce, M. Blanchon, N. Lyn, M. Maski View Poster Introduction: As the spectrum of Fabry phenotypes remains uncertain, the study objective was to describe patterns of progression in untreated Fabry disease (FD) patients from a large electronic […]
Unmet medical needs in people with type 2 diabetes treated by insulin: results from the International Diabetes Management Practices Survey (IDMPS)
Event: EASD (European Association for the Study of Diabetes) Annual Meeting 2019, Barcelona, SpainAuthors: A. Ramachandran, JC. Mbanya, P. Aschner, JJ. Gagliardino, H. Ilkova, F. Lavalle, M; Shestakova, J-M. Chantelot, A. Shaunik, A. Alvarez, M. Rollot, J. CN Chan View Poster Background and aims Limited data exist on the impact of different insulin therapy regimes on […]
Projeter l’efficacité d’un traitement en vie réelle (VR) à partir d’une étude clinique randomisée (ECR) : une approche utilisant le suréchantillonnage
Event: 11ème Colloque Données de Santé en vie réelle 2019, AFCROs, Paris, France Authors: C. Esnault, M. Génin, S. Ekhtiari, A. Civet View Poster Introduction Bien qu’il n’y ait pas encore de consensus formel sur l’emploi des modèles statistiques pour estimer l’efficacité d’un traitement en VR, le besoin de son évaluation plus systématique est largement reconnu [1] […]
Compare renal function preservation outcome of SGLT2 Inhibitor vs. DPP4 Inhibitor in patients with type 2 diabetes: a retrospective cohort study of Japanese commercial database with advanced analytics approach
Event: ISPOR Europe 2018, Barcelona, Spain Authors: F.L. Zhou, H. Watada, Y. Tajima, M. Berthelot, D. Kang, C. Esnault, Y. Shuto, H. Maegawa, D. Koya View Poster Background Tofogliflozin, a highly selective sodium/glucose cotransporter 2 inhibitor (SGLT2i), was approved in Japan for Type 2 Diabetes Mellitus (T2DM) in May 2014. It is marketed as Apleway/Deberza, […]
A machine learning algorithm can identify clusters of patients with favourable glycaemic outcomes in a pooled European Gla-300 studies (REALI): Novel signposts for clinicians?
Event: EASD Annual Meeting 2018, Berlin, Germany Authors: M. Rollot, M. Bonnemaire, C. Brulle-Wohlhueter, L. Pedrazzini, E. Boëlle-Le Corfec, G. Bigot, M. Didac, R. Bonadonna, P. Gourdy, D. Müller-Wieland, O. Hacman, A. Chiorean, N. Freemantle View Poster Background and aims Detecting consistent patterns of interest can be performed using data-driven subgroup discovery algorithms. These may be instrumental […]
Bioinformatics modelling of baseline characteristics to predict clinical outcomes and responses in the LixiLan-L trial
Event: International Diabetes Federation (IDF) Congress, Abu Dhabi, UAE Authors: P. Fogel, A. Civet, T. Fan, A. Shaunik, C. Brulle-Wohlhueter, Y. Gaston-Mathe View Poster Background Identifying categories of patients with diabetes sharing common characteristics and analysing clinical outcomes in these groups may lead to better understanding of patient diversity and generate hypotheses on disease-driving mechanisms. […]
Using machine learning algorithms to identify predictive factors of clinical outcomes with iGlarLixi or iGlar in the LixiLan-L trial
Event: Annual Meeting of the European Association for the Study of Diabetes (EASD) 2017, Lisbon, Portugal Authors: Y. Gaston-Mathé, T. Fan, A. Shaunik, C.Brulle-Wohlhueter, A. Civet View Poster
Patients with Severe Dry Eye Disease in Routine Clinical Practice in the UK – Physician and Patient’s Assessments
Event: Association for Research in Vision and Ophthalmology (ARVO)’s 2015 Annual Meeting, Denver, USA Authors: M. Amrane, A. Civet, D. Kang, A. Templier, M.S. Figueiredo, F.C. Figueiredo View Poster Objectives Severity of kerato conjunctivissicca (KCS) can be defined in several ways that are not always convergent. One central question remains, how to reconcile physician and […]
